Program
Valproic Acid
Also written as “Divalproex Sodium”, “divalproex sodium” and “Sodium valproate”.
Its studies are mostly in Bipolar Disorder · Epilepsy · Migraine Disorders · Seizures · Schizophrenia, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbott | 100 open or running | phase 3since May 15, 2003 | May 15, 2003 | none ahead |
| Dr. Reddy's Laboratories | 70 open or running | phase 1since Jan 25, 2010 | Jan 25, 2010 | none ahead |
| Sanofi | 40 open or running | phase 4since Dec 9, 2005 | Dec 9, 2005 | none ahead |
| Teva Pharmaceutical Industries | 40 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| AstraZeneca | 30 open or running | phase 4since Aug 29, 2005 | Apr 9, 2004 | none ahead |
| Novartis | 30 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Desitin Arzneimittel | 20 open or running | phase 1since Dec 21, 2023 | Dec 21, 2023 | none ahead |
| Viatris | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| cerebral-therapeutics-llc | 10 open or running | phase 2since Sep 3, 2016 | Sep 3, 2016 | none ahead |
| hearthstone-alzheimer-care | 10 open or running | phase 1since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| tecnoquimicas | 10 open or running | phase 4since Apr 11, 2019 | Apr 11, 2019 | none ahead |
Also a collaborator on its studies: biopharma-services-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since May 15, 2003.
- Mar 25, 2008Phase 2 study in Pediatric EpilepsyAbbott · NCT00646711 · 16 enrolled · United States
- Mar 30, 2008Viatris's first studies: 2 phase 1 studies in HealthyNew to ViatrisViatris · NCT00648076, NCT00647712
- Jan 30, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00834990, NCT00834639
- Mar 17, 2009Novartis's first study: phase 1 study in SeizuresNew to NovartisNovartis · NCT00864006 · 28 enrolled
- Jun 2, 20092 phase 1 studies in EpilepsyNovartis · NCT00913874, NCT00913848
- Sep 9, 20092 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT00974441, NCT00974012
- Jan 25, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01056627, NCT01055938
- May 26, 20103 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01132196, NCT01132183, NCT01132170
- Apr 4, 20122 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01581788, NCT01581775
- Sep 3, 2016cerebral-therapeutics-llc's first study: phase 2 study in EpilepsyNew to cerebral-therapeutics-llccerebral-therapeutics-llc · NCT02899611 · 6 enrolled · Australia
- Sep 14, 2018Phase 1 study in EpilepsySanofi · NCT03681158 · 5 enrolled · United Kingdom
- Apr 11, 2019tecnoquimicas's first study: phase 4 study in HealthyNew to tecnoquimicastecnoquimicas · NCT03914534 · 30 enrolled · Colombia
- Dec 21, 2023Desitin Arzneimittel's first study: phase 1 study in Food-drug InteractionNew to Desitin ArzneimittelDesitin Arzneimittel · NCT06211283 · 28 enrolled · Canada
- Jan 10, 2024Phase 1 study in Multiple Drug UseDesitin Arzneimittel · NCT06214130 · 22 enrolled · Canada
TargetBeta
“Succinate semialdehyde dehydrogenase inhibitor; Succinate semialdehyde dehydrogenase inhibitor; Succinate semialdehyde dehydrogenase inhibitor”ChEMBL 37, by rule
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06214130Multiple Drug Use · Canada | 1 | Completed | Desitin Arzneimittel | Nov 6, 2023 | 22 |
| NCT06211283Food-drug Interaction · Canada | 1 | Completed | Desitin Arzneimittel | Oct 20, 2023 | 28 |
| NCT03914534Healthy · Colombia | 4 | Completed | tecnoquimicas | Jul 31, 2018 | 30 |
| NCT03681158Epilepsy · United Kingdom | 1 | Completed | Sanofi | Apr 11, 2019 | 5 |
| NCT02899611Epilepsy · Australia | 2 | Completed | cerebral-therapeutics-llc | Jun 1, 2021 | 6 |
| NCT01581788Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Feb 2011 | 54 |
| NCT01581775Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jan 2011 | 54 |
| NCT01132196Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2006 | 34 |
| NCT01132183Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Mar 2007 | 34 |
| NCT01132170Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Sep 2006 | 34 |
| NCT01056627Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jan 2007 | 34 |
| NCT01055938Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jan 2007 | 34 |
| NCT00974441Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2006 | 48 |
| NCT00974012Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Oct 2006 | 24 |
| NCT00913874Epilepsy | 1 | Completed | Novartis | Oct 2005 | 30 |
| NCT00913848Epilepsy | 1 | Completed | Novartis | Oct 2005 | 30 |
| NCT00864006Seizures | 1 | Completed | Novartis | Oct 2006 | 28 |
| NCT00834990Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2003 | 24 |
| NCT00834639Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2003 | 24 |
| NCT00648076Healthy · United States | 1 | Completed | Viatris | Dec 2004 | 40 |
| NCT00647712Healthy · United States | 1 | Completed | Viatris | Dec 2004 | 38 |
| NCT00646711Pediatric Epilepsy · United States | 2 | Completed | Abbott | Dec 2003 | 16 |
| NCT00431522Bipolar Disorder · Turkey | 4 | Completed | Sanofi | Oct 2006 | 58 |
| NCT00271258Bipolar Disorder · France | 3 | Completed | Sanofi | 200 | |
| NCT00264173Bipolar Disorder | 4 | Completed | Sanofi | 270 | |
| NCT00195806Migraine Disorders · United States | 3 | Completed | Abbott | 315 | |
| NCT00195780Bipolar I Disorder · United States | 3 | Completed | Abbott | 227 | |
| NCT00195767Mania · United States | 3 | Completed | Abbott | 150 | |
| NCT00195754Migraine Disorders · United States | 3 | Completed | Abbott | 114 | |
| NCT00195741Migraine Disorders · United States | 3 | Completed | Abbott | 300 | |
| NCT00197834Dementia · United States | 1 | UNKNOWN | hearthstone-alzheimer-care | 20 | |
| NCT00139074Bipolar Disorder · Denmark | 4 | Terminated | AstraZeneca | Jun 2006 | 17 |
| NCT00114686Alcoholism · United States | 3 | Completed | AstraZeneca | 350 | |
| NCT00102713Seizures · United States | 3 | Completed | Abbott | 50 | |
| NCT00081380Bipolar Disorder · United States, Canada | 3 | Completed | AstraZeneca | 710 | |
| NCT00067431Epilepsies, Partial · United States | 3 | Terminated | Abbott | 300 | |
| NCT00067262Bipolar Disorder · United States | 3 | Completed | Abbott | 150 | |
| NCT00060905Bipolar Disorder · United States | 3 | Completed | Abbott | 370 |
How it is read
Names in the registry
- “Divalproex Sodium”, 10 entries
- “divalproex sodium”, 7 entries
- “Sodium valproate”, 3 entries
- “Valproic Acid”, 2 entries
- “Valproic Acid 500 MG”, 2 entries
Conditions, from the studies’ own filings
- Bipolar Disorder, 9 studies
- Epilepsy, 7 studies
- Migraine Disorders, 3 studies
- Seizures, 2 studies
- Schizophrenia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.